February 27, 2018 / 11:14 AM / 3 months ago

Generic drugmaker Endo's loss narrows as impairment charges drop

Feb 27 (Reuters) - Generic drugmaker Endo International Plc reported a smaller fourth-quarter loss on Tuesday, due to lower asset impairment charges.

Net loss attributable to shareholders narrowed to $368.4 million, or $1.65 per share, in the quarter ended Dec. 31, from $3.34 billion, or $14.98 per share, a year earlier.

The Dublin, Ireland-based company recorded asset impairment charges of $130.45 million in the latest quarter, much less than the $3.52 billion charges it took a year ago.

Total revenue fell to $768.6 million from $1.24 billion. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Savio D’Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below